195 related articles for article (PubMed ID: 24846673)
21. Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids.
Marker CL; Luján R; Loh HH; Wickman K
J Neurosci; 2005 Apr; 25(14):3551-9. PubMed ID: 15814785
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, Biological Evaluation, and Utility of Fluorescent Ligands Targeting the μ-Opioid Receptor.
Schembri LS; Stoddart LA; Briddon SJ; Kellam B; Canals M; Graham B; Scammells PJ
J Med Chem; 2015 Dec; 58(24):9754-67. PubMed ID: 26632862
[TBL] [Abstract][Full Text] [Related]
23. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
24. [Distinct mechanisms underlying pleasure and analgesia].
Ide S; Minami M; Satoh M; Sora I; Ikeda K
Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):11-5. PubMed ID: 15738616
[No Abstract] [Full Text] [Related]
25. μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons.
Sadeghi M; Tzschentke TM; Christie MJ
Br J Pharmacol; 2015 Jan; 172(2):460-8. PubMed ID: 24372103
[TBL] [Abstract][Full Text] [Related]
26. A review of the existing literature on buprenorphine pharmacogenomics.
Meaden CW; Mozeika A; Asri R; Santos CD
Pharmacogenomics J; 2021 Apr; 21(2):128-139. PubMed ID: 33154520
[TBL] [Abstract][Full Text] [Related]
27. Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons.
Halikere A; Popova D; Scarnati MS; Hamod A; Swerdel MR; Moore JC; Tischfield JA; Hart RP; Pang ZP
Mol Psychiatry; 2020 Jul; 25(7):1406-1419. PubMed ID: 31481756
[TBL] [Abstract][Full Text] [Related]
28. Morphine mediates a proinflammatory phenotype via μ-opioid receptor-PKCɛ-Akt-ERK1/2 signaling pathway in activated microglial cells.
Merighi S; Gessi S; Varani K; Fazzi D; Stefanelli A; Borea PA
Biochem Pharmacol; 2013 Aug; 86(4):487-96. PubMed ID: 23796752
[TBL] [Abstract][Full Text] [Related]
29. Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in mu-opioid receptor knockout mice.
Ide S; Minami M; Ishihara K; Uhl GR; Satoh M; Sora I; Ikeda K
Neuropharmacology; 2008 Jun; 54(8):1182-8. PubMed ID: 18417173
[TBL] [Abstract][Full Text] [Related]
30. [Individual differences in analgesic effects of narcotics].
Ide S; Kasai S; Ikeda K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Feb; 28(1):43-8. PubMed ID: 18411709
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.
Browne CA; Erickson RL; Blendy JA; Lucki I
Neuropharmacology; 2017 May; 117():401-407. PubMed ID: 28188737
[TBL] [Abstract][Full Text] [Related]
32. The μ-opioid receptor gene polymorphism 118A>G weakens the pharmacological action of buprenorphine.
Imai H; Morita M; Morita H; Ohyama T; Tanaka S; Uchida S; Namiki N; Uemura N; Ohashi K
Int J Clin Pharmacol Ther; 2020 Nov; 58(11):626-633. PubMed ID: 32870152
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine phosphorylation of the mu-opioid receptor regulates agonist intrinsic efficacy.
McLaughlin JP; Chavkin C
Mol Pharmacol; 2001 Jun; 59(6):1360-8. PubMed ID: 11353794
[TBL] [Abstract][Full Text] [Related]
34. Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor.
Nowoczyn M; Marie N; Coulbault L; Hervault M; Davis A; Hanouz JL; Allouche S
Neuropharmacology; 2013 Oct; 73():368-79. PubMed ID: 23792280
[TBL] [Abstract][Full Text] [Related]
35. Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).
Knapman A; Connor M
Br J Pharmacol; 2015 Jan; 172(2):349-63. PubMed ID: 24527749
[TBL] [Abstract][Full Text] [Related]
36. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
[TBL] [Abstract][Full Text] [Related]
37. A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells.
Knapman A; Santiago M; Du YP; Bennallack PR; Christie MJ; Connor M
J Biomol Screen; 2013 Mar; 18(3):269-76. PubMed ID: 23015017
[TBL] [Abstract][Full Text] [Related]
38. Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function.
Mague SD; Port RG; McMullen ME; Carlson GC; Turner JR
Neuropharmacology; 2015 Oct; 97():426-35. PubMed ID: 25986698
[TBL] [Abstract][Full Text] [Related]
39. A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.
Brasel CM; Sawyer GW; Stevens CW
Eur J Pharmacol; 2008 Dec; 599(1-3):36-43. PubMed ID: 18930720
[TBL] [Abstract][Full Text] [Related]
40. Drug Binding Poses Relate Structure with Efficacy in the μ Opioid Receptor.
Sutcliffe KJ; Henderson G; Kelly E; Sessions RB
J Mol Biol; 2017 Jun; 429(12):1840-1851. PubMed ID: 28502792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
